US7129350B2 - Coupling process and intermediates useful for preparing cephalosporins - Google Patents
Coupling process and intermediates useful for preparing cephalosporins Download PDFInfo
- Publication number
- US7129350B2 US7129350B2 US10/776,795 US77679504A US7129350B2 US 7129350 B2 US7129350 B2 US 7129350B2 US 77679504 A US77679504 A US 77679504A US 7129350 B2 US7129350 B2 US 7129350B2
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- alkyl
- aforesaid
- conducted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JYOYDYYYMLKKFT-NYNCVSEMSA-N N[C@@H]([C@H]1SCC([C@H]2OCCC2)=C(C(O)=O)N11)C1=O Chemical compound N[C@@H]([C@H]1SCC([C@H]2OCCC2)=C(C(O)=O)N11)C1=O JYOYDYYYMLKKFT-NYNCVSEMSA-N 0.000 description 6
- 0 *OC(C(N([C@@]([C@@]1N)SC2)C1=O)=C2[C@]1OCCC1)=O Chemical compound *OC(C(N([C@@]([C@@]1N)SC2)C1=O)=C2[C@]1OCCC1)=O 0.000 description 4
- VNLXVBXGBKIZHZ-UHFFFAOYSA-N CN=C(C)C(=O)C(C)C Chemical compound CN=C(C)C(=O)C(C)C VNLXVBXGBKIZHZ-UHFFFAOYSA-N 0.000 description 4
- QSJXEFYPDANLFS-UHFFFAOYSA-N CC(=O)C(C)=O Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- UJRYVMGEUBWKNM-OREWDNAWSA-N [H][C@@]1(C)C(=O)N2C(C)=C(C3CCCO3)CS[C@@]21[H] Chemical compound [H][C@@]1(C)C(=O)N2C(C)=C(C3CCCO3)CS[C@@]21[H] UJRYVMGEUBWKNM-OREWDNAWSA-N 0.000 description 2
- UOQFZGVGGMHGEE-UHFFFAOYSA-N CC(=O)C(O)O Chemical compound CC(=O)C(O)O UOQFZGVGGMHGEE-UHFFFAOYSA-N 0.000 description 1
- WHTJHCZEXHCCGR-UHFFFAOYSA-N CON=C(C(=O)O)C1=CN=C(N)S1 Chemical compound CON=C(C(=O)O)C1=CN=C(N)S1 WHTJHCZEXHCCGR-UHFFFAOYSA-N 0.000 description 1
- PAHJCWJYAWKUEF-UHFFFAOYSA-N CON=C(C(C)=O)C1=CN=C(N)S1 Chemical compound CON=C(C(C)=O)C1=CN=C(N)S1 PAHJCWJYAWKUEF-UHFFFAOYSA-N 0.000 description 1
- GYLXQTLPGLXNLU-BWHRIENRSA-M II.[H][C@@]1(C)C(=O)N2C(C)=C(C3CCCO3)CS[C@@]21[H].[H][C@@]1(N)C(=O)N2C(C(=O)O)=C([C@@H]3CCCO3)CS[C@@]21[H].[V]I Chemical compound II.[H][C@@]1(C)C(=O)N2C(C)=C(C3CCCO3)CS[C@@]21[H].[H][C@@]1(N)C(=O)N2C(C(=O)O)=C([C@@H]3CCCO3)CS[C@@]21[H].[V]I GYLXQTLPGLXNLU-BWHRIENRSA-M 0.000 description 1
- JGHAXGGAYIZVLN-LVJSCHTASA-N II.[H][C@@]1(N)C(=O)N2C(C(=O)O)=C([C@@H]3CCCO3)CS[C@@]21[H] Chemical compound II.[H][C@@]1(N)C(=O)N2C(C(=O)O)=C([C@@H]3CCCO3)CS[C@@]21[H] JGHAXGGAYIZVLN-LVJSCHTASA-N 0.000 description 1
- YGYHXHKXCQHOLY-RGMNGODLSA-N O=C(C[Y])[C@@H]1CCCO1 Chemical compound O=C(C[Y])[C@@H]1CCCO1 YGYHXHKXCQHOLY-RGMNGODLSA-N 0.000 description 1
- SJNGYEVDQWNIQP-LURJTMIESA-N O=C(O)CC(=O)[C@@H]1CCCO1 Chemical compound O=C(O)CC(=O)[C@@H]1CCCO1 SJNGYEVDQWNIQP-LURJTMIESA-N 0.000 description 1
- UJJLJRQIPMGXEZ-BYPYZUCNSA-N O=C(O)[C@@H]1CCCO1 Chemical compound O=C(O)[C@@H]1CCCO1 UJJLJRQIPMGXEZ-BYPYZUCNSA-N 0.000 description 1
- JYOYDYYYMLKKFT-PZUJBFCGSA-N [H][C@@]1(N)C(=O)N2C(C(=O)O)=C(C3CCCO3)CS[C@@]21[H] Chemical compound [H][C@@]1(N)C(=O)N2C(C(=O)O)=C(C3CCCO3)CS[C@@]21[H] JYOYDYYYMLKKFT-PZUJBFCGSA-N 0.000 description 1
- DWEQVBLZBYKMPL-QNLJLNITSA-N [H][C@@]1(NC(=O)/C(=N\OC)C2=CN=C(N)S2)C(=O)N2C(C(=O)OCC=C)=C([C@@H]3CCCO3)CS[C@@]21[H] Chemical compound [H][C@@]1(NC(=O)/C(=N\OC)C2=CN=C(N)S2)C(=O)N2C(C(=O)OCC=C)=C([C@@H]3CCCO3)CS[C@@]21[H] DWEQVBLZBYKMPL-QNLJLNITSA-N 0.000 description 1
- LSNAXTIAQANMEK-FIJJEHCQSA-M [H][C@@]1(NC(=O)/C(=N\OC)C2=CN=C(N)S2)C(=O)N2C(C(=O)[O-])=C(C3CCCO3)CS[C@@]21[H].[Na+] Chemical compound [H][C@@]1(NC(=O)/C(=N\OC)C2=CN=C(N)S2)C(=O)N2C(C(=O)[O-])=C(C3CCCO3)CS[C@@]21[H].[Na+] LSNAXTIAQANMEK-FIJJEHCQSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D501/06—Acylation of 7-aminocephalosporanic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- This invention relates to a novel process for the preparation of 3-cyclic-ether-substituted cephalosporins.
- the invention also relates to novel processes for preparing zwitterions, para-nitrobenzyl esters and allyl esters useful in the preparation of the above cephalosporins.
- the invention also relates to 3-cyclic-ether-substituted cephalosporins. These compounds possess certain advantageous properties, such as crystalline form and high enantiomeric excess (e.e.).
- the 3-cyclic-ether-substituted cephalosporins prepared by the methods of the present invention have prolonged and high levels of antibacterial activity and possess good absorption parentally in humans and animals.
- the 3-cyclic-ether-substituted cephalosporins prepared by the processes of the present invention contain a cyclic ether substituent at carbon 3 of the cephalosporin nucleus.
- GB 1405758 describes alternative methods of preparation of certain 3-cyclic-ether-substituted cephalosporins.
- the present inventors have discovered a novel compound of formula I, as defined herein below.
- the present inventors have also discovered a high-yielding process for the preparation of said compounds of formula I.
- the present invention relates to a process for the preparation of a 3-cyclic-ether-substituted cephalosporin of the formula I
- the group CO 2 R 1 is a carboxylic acid or a carboxylate salt
- R 2 has a formula:
- a 1 is C 6-10 aryl, C 1-10 heteroaryl or C 1-10 heterocyclyl
- a 2 is hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, C 6-10 aryl, C 1-6 alkyl(CO)(C 1-6 )alkyl-O—, HO(CO)(C 1-6 )alkyl, mono-(C 6-10 aryl)(C 1-6 alkyl), di-(C 6-10 aryl)(C 1-6 alkyl) or tri-(C 6-10 aryl)(C 1-6 alkyl);
- the aforesaid process may be performed in the presence of a coupling agent and a catalyst.
- the group OA 2 of said compounds of formula III is cis to the amide linkage, i.e., the Z-configuration is preferred.
- Suitable solvents for the aforesaid process of conversion of compounds of formula II into compounds of formula I of the invention include water, acetone, tetrahydrofuran, ethyl acetate, dimethylacetamide, dimethylformamide, acetonitrile, methylene chloride, 1,2-dichloroethane or mixtures thereof.
- the solvent is tetrahydrofuran.
- the solvent is ethyl acetate:
- the solvent is water, acetone or mixtures thereof. More preferably the solvent is a mixture of acetone and water. Most preferably the solvent is a 1.3:1 mixture of acetone and water.
- Suitable bases for the aforesaid conversion of the invention include diisopropylethylamine or sodium hydroxide.
- the base is sodium hydroxide, most preferably 15% aqueous sodium hydroxide.
- Suitable coupling agents for the aforesaid conversion of the invention include N,N′-diethylcarbodiimide, N,N′-dipropyl carbodiimide, N,N′-diisopropylcarbodiimide, N,N′-dicyclohexylcarbodiimide, N-ethyl-N′-[3-(dimethylamino)propyl]carbodiimide, N,N′-carbonyldiimidazole or N,N′-carbonyldithiazole.
- a preferred coupling agent is N,N′-dicyclohexylcarbodiimide.
- the aforesaid conversion is conducted in the absence of any coupling agents.
- Suitable catalysts for the aforesaid conversion of the invention include Lewis acids.
- Suitable Lewis acids are selected from the group consisting of boron trihalide, such as boron tribromide, and aluminum halide, such as aluminum chloride.
- the aforesaid conversion is conducted in the absence of any catalysts.
- the aforesaid conversion of the invention can be conducted at a temperature of about ⁇ 40° C. to about +30° C., preferably about +20° C. to about +30° C.
- the aforesaid process can be conducted for a period from about 1 hour to about 24 hours; preferably about 3 hours.
- Suitable leaving groups L of the aforesaid compound of formula III of the aforesaid conversion include hydroxy, halo, azido, mono(C 1-6 alkyl)carbonate, (C 1-6 alkyl)carboxylate, (C 6-10 aryl)carboxylate, mono-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di-(C 6-10 aryl)(C 6-10 alkyl)carboxylate, di(C 1-6 alkyl)phosphorothioate, (C 1-6 alkyl)sulfonyl, mono-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, di-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, (C 1-6 alkyl)-(CO)—S—, cyano-C 1-6 alkoxy, C 6-10 aryloxy, 3-benzthiazolyloxy, 8-quinolinyloxy
- the leaving group L of the compound of formula III is selected from the group consisting of hydroxy, halo and azido.
- the leaving group L of the compound of formula III is selected from the group consisting of mono(C 1-6 alkyl)carbonate, (C 1-6 alkyl)carboxylate, (C 6-10 aryl)carboxylate, mono-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di-(C 6-10 aryl)(C 1-6 alkyl)carboxylate and di(C 1-6 alkyl)phosphorothioate.
- the leaving group L of the compound of formula III is selected from the group consisting of (C 1-6 alkyl)sulfonyl, mono-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, di-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl and (C 1-6 alkyl)-(CO)—S—.
- the leaving group L of the compound of formula III is selected from the group consisting of cyano-C 1-6 alkoxy, C 6-10 aryloxy, 3-benzthiazolyloxy, 8-quinolinyloxy and N-oxy-succinimidyl.
- the leaving group L of the compound of formula III is selected from the group consisting of halo, methanesulfonyl, diethylphosphorothioate and 3-benzthiazolyloxy.
- the leaving group L of the compound of formula III is di(C 1-6 alkyl)phosphorothioate, more preferably diethylphosphorothioate.
- the present invention also relates to an alternative process for the preparation of the above 3-cyclic-ether-substituted cephalosporin of the formula I, or the pharmaceutically acceptable salts thereof, comprising reacting a compound of formula V
- R 2 has the formula
- a 1 is C 6-10 aryl, C 1-10 heteroaryl or C 1-10 heterocyclyl
- a 2 is hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkenyl, C 6-10 aryl, C 1-6 alkyl(CO)(C 1-6 )alkyl-O—, HO(CO)(C 1-6 )alkyl, mono-(C 6-10 aryl)(C 1-6 alkyl), di-(C 6-10 aryl)(C 1-6 alkyl) or tri-(C 6-10 aryl)(C 1-6 alkyl); and R 3 is para-nitrobenzyl or allyl, preferably allyl; with a suitable deprotecting agent in the presence of a solvent.
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched moieties or combinations thereof. alkyl groups, wherever they occur, may be optionally substituted by a suitable substituent.
- cycloalkyl includes a mono or bicyclic carboxcyclic ring (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptal, cyclooctyl, cyclononyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl and bicyclo[5.2.0]nonanyl, etc.); optionally substituted by 1 to 3 suitable substituents as defined below such as fluoro, chloro, trifluoromethyl, (C 1-4 )alkoxy, (C 6-10 )aryloxy, trifluoromethoxy, difluoromethoxy or (C 1-4 )alkyl, more preferably fluoro, chloro, methyl, ethyl or methoxy.
- suitable substituents as defined below such as fluoro, chloro, trifluoromethyl, (C 1-4 )alkoxy, (C 6-10
- cycloalkenyl includes a monocarbocyclic ring (e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc.) optionally substituted by 1 to 3 suitable substituents as defined below such as fluoro, chloro, trifluoromethyl, (C 1-4 )alkoxy, (C 6-10 )aryloxy trifluoromethoxy, difluoromethoxy or (C 1-4 )alkyl, more preferably fluoro, chloro, methyl, ethyl or methoxy.
- suitable substituents as defined below such as fluoro, chloro, trifluoromethyl, (C 1-4 )alkoxy, (C 6-10 )aryloxy trifluoromethoxy, difluoromethoxy or (C 1-4 )alkyl, more preferably fluoro, chloro, methyl, ethyl or methoxy
- alkoxy includes O-alkyl groups wherein “alkyl” is as defined above.
- halo as used herein, unless otherwise indicated, includes fluorine, chlorine, bromine or iodine, preferably bromine or chlorine.
- aryl includes an organic radical derived from an aromatic hydrocarbon by removal of one or more hydrogen(s), such as phenyl or naphthyl, optionally substituted by 1 to 3 suitable substituents such as fluoro, chloro, cyano, nitro, trifluoromethyl, (C 1-6 )alkoxy, (C 6-10 )aryloxy, (C 3-8 )cycloalkyloxy, trifluoromethoxy, difluoromethoxy or (C 1-6 )alkyl.
- suitable substituents such as fluoro, chloro, cyano, nitro, trifluoromethyl, (C 1-6 )alkoxy, (C 6-10 )aryloxy, (C 3-8 )cycloalkyloxy, trifluoromethoxy, difluoromethoxy or (C 1-6 )alkyl.
- heteroaryl includes an organic radical derived from an aromatic heterocyclic compound by removal of one or more hydrogen(s), such as benzimidazolyl, benzofuranyl, benzofurazanyl, 2H-1-benzopyranyl, benzothiadiazine, benzothiazinyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, furazanyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, phthalazinyl, pteridinyl, purin
- benzimidazolyl such as benzimid
- a group derived from pyrrole can be C-attached or N-attached where such is possible.
- a group derived from pyrrole can be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
- heterocyclyl includes an organic radical derived from a non-aromatic heterocyclic compound by removal of one or more hydrogens, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]-heptanyl, azetidinyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dioxanyl, 1,3-dioxolanyl, 1,4-dithianyl, hexahydroazepinyl, hexahydropyrimidine, imidazolidinyl, imidazolinyl, isoxazolidinyl, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, 2H-pyranyl, 4H-pyranyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, 2-pyrrolinyl,
- the foregoing groups can be C-attached or N-attached where such is possible.
- a group derived from piperidine can be piperidin-1-yl (N-attached) or piperidin-4-yl (C-attached).
- the foregoing groups, as derived from the compounds listed above can be optionally substituted where such is possible by a suitable substituent, such as oxo, F, Cl, Br, CN, OH, (C 1-4 )alkyl, (C 1-4 )perfluoroalkyl, (C 1-4 )perfluoroalkoxy, (C 1-4 )alkoxy, or (C 3-8 )cycloalkyloxy.
- a suitable substituent is intended to mean a chemically and pharmaceutically acceptable functional group i.e., a moiety that does not negate the inhibitory activity of the inventive compounds.
- suitable substituents may be routinely selected by those skilled in the art.
- Illustrative examples of suitable substituents include, but are not limited to halo groups, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, hydroxy groups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy or heteroaryloxy groups, aralkyl or heteroaralkyl groups, aralkoxy or heteroaralkoxy groups, carboxy groups, amino groups, alkyl- and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups dialkylamino carbonyl groups, arylcarbonyl groups, aryl
- carboxylate salt includes metal salts (such as aluminium, alkali metal salts, such as sodium or potassium, preferably sodium), alkaline earth metal salts (such as calcium or magnesium), and ammonium salts.
- the ammonium salts can be substituted with C 1-6 alkylamines (such as triethylamine), hydroxy-(C 1-6 )alkylamines (such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, or tris-(2-hydroxyethyl)amine), cycloalkylamines (such as dicyclohexylamine), procaine, dibenzylamine, N,N-dibenzylethylenediamine, 1-ephenamine, N-methylmorpholine, N-ethylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N′-bis-dehydro-abietylamine, ethylenediamine,
- active compounds refers to compounds of formula I.
- the group OA 2 of said compounds of formula III is cis to the amide linkage, i.e., the Z-configuration is preferred.
- Suitable deprotecting agents for the aforesaid process of conversion of compounds of formula V into compounds of formula I of the invention include sodium dithionite or tetrakis triphenyl phosphine palladium (0).
- Suitable solvents for the aforesaid conversion include acetone, water, tetrahydrofuran, methylene chloride or mixtures thereof.
- the solvent is methylene chloride, tetrahydrofuran or mixtures thereof.
- the solvent is tetrahydrofuran.
- the solvent is methylene chloride.
- the aforesaid conversion may be conducted at a temperature of about 0° C. to about 45° C.
- the aforesaid conversion may be conducted for a period from about 1 hour to about 24 hours.
- R 3 is para-nitrobenzyl.
- the deprotecting agent is sodium dithionite.
- the aforesaid conversion is conducted at a temperature of about 40° C.
- the aforesaid process is conducted for about 4 hours.
- R 3 is allyl.
- the preferred deprotecting agent is tetrakis triphenyl phosphine palladium (0).
- the aforesaid process is conducted at a temperature of about 20° C. to about 35° C.; preferably about 27° C. to about 30° C. Within this embodiment, preferably the aforesaid process is conducted for about 5 hours.
- the present invention also includes a process for the preparation of the above compound of formula II comprising reacting a compound of formula IV
- R 3 is para-nitrobenzyl or allyl, preferably para-nitrobenzyl; and X is halo, preferably chloro; with a suitable deprotecting agent; in the presence of a solvent.
- Suitable solvents for the process of conversion of compounds of formula IV into compounds of formula II of the invention include acetone, water, tetrahydrofuran, methylene chloride or mixtures thereof.
- the solvent is acetone, water, tetrahydrofuran or mixtures thereof.
- the solvent is a mixture of acetone and, water. More preferably, the-solvent is a 3:1 mixture of acetone and water.
- Suitable deprotecting agents for the aforesaid conversion include sodium dithionite, catalytic hydrogenating agent (such as hydrogen gas over 10% palladium over carbon) or tetrakis triphenyl phosphine palladium (0).
- the aforesaid conversion may be conducted at a temperature of about 0° C. to about 45° C.
- the aforesaid conversion may be conducted for a period from about 1 hour to about 24 hours.
- R 3 is para-nitrobenzyl.
- the preferred deprotecting agent is sodium dithionite.
- the aforesaid process is conducted at a temperature of about 45° C.
- the aforesaid process is conducted at a temperature of about 1 hour.
- R 3 is allyl.
- the deprotecting agent is tetrakis triphenyl phosphine palladium (0).
- Suitable solvents include methylene chloride and tetrahydrofuran. The aforesaid process can be conducted at a temperature of about 20° C. to about 35° C.
- the present invention also relates to a process for the preparation of the above compound of formula V comprising reacting the above compound of formula IV, wherein R 3 is para-nitrobenzyl or allyl; preferably allyl; and X is halo; preferably chloro; with a compound of the formula III, as defined above, in the presence of a solvent.
- the aforesaid process can be conducted in the presence of an optional coupling agent or an optional catalyst.
- Suitable solvents for the aforesaid conversion of compounds of formula IV into compounds of formula V include methylene chloride, tetrahydrofuran or mixtures thereof.
- a coupling agent is used.
- suitable coupling agents include N,N′-diethylcarbodiimide, N,N′-dipropyl carbodiimide, N,N′-diisopropylcarbodiimide, N,N′-dicyclohexylcarbodiimide, N-ethyl N′-[3-(dimethylamino)propyl]carbodiimide, N,N′-carbonyldiimidazole or N,N′-carbonyldithiazole.
- a preferred coupling agent is N,N′-dicyclohexylcarbodiimide.
- the aforesaid conversion is conducted in the absence of any coupling agents.
- a catalyst is used.
- the catalyst can be a Lewis acid. Suitable Lewis acids are boron trihalide, such as boron tribromide, or aluminum halide, such as aluminum chloride.
- the aforesaid conversion is conducted in the absence of any catalysts.
- the aforesaid conversion may be conducted at a temperature of about ⁇ 40° C. to about +40° C.
- the aforesaid conversion may be conducted for a period of from about 1 hour to about 24 hours.
- R 3 is para-nitrobenzyl.
- the aforesaid conversion is conducted at a temperature of about +20° C. to about +30° C.
- the aforesaid conversion is conducted for about 3 hours.
- R 3 is allyl.
- the solvent is methylene chloride.
- the aforesaid conversion is conducted at a temperature of about 20° C. to about 40° C. Within this embodiment, preferably the aforesaid conversion is conducted for about 24 hours.
- the leaving group L of the compound of formula III in the aforesaid conversion of the invention includes hydroxy, halo, azido, mono(C 1-6 alkyl)carbonate, (C 1-6 alkyl)carboxylate, (C 6-10 aryl)carboxylate, mono-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di(C 1-6 alkyl)phosphorothioate, (C 1-6 alkyl)sulfonyl, mono-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, di-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, (C 1-6 alkyl)-(CO)—S—, cyano-C 1-6 alkoxy, C 6-10 aryloxy, 3-benzthiazolyloxy, 8-quinolinyloxy or N
- the leaving group L of the compound of formula III is selected from the group consisting of hydroxy, halo and azido.
- the leaving group L of the compound of formula III is selected from the group consisting of mono(C 1-6 alkyl)carbonate, (C 1-6 alkyl)carboxylate, (C 6-10 aryl)carboxylate, mono-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di-(C 6-10 aryl)(C 1-6 alkyl)carboxylate and di(C 1-6 alkyl)phosphorothioate.
- the leaving group L of the compound of formula III is selected from the group consisting of (C 1-6 alkyl)sulfonyl, mono-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, di-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl and (C 1-6 alkyl)-(CO)—S—.
- the leaving group L of the compound of formula III is selected from the group consisting of cyano-C 1-6 alkoxy, C 6-10 aryloxy, 3-benzthiazolyloxy, 8-quinolinyloxy and N-oxy-succinimidyl.
- the leaving group L of the compound of formula III is selected from the group consisting of halo, methanesulfonyl, diethylphosphorothioate and 3-benzthiazolyloxy.
- the leaving group L of the compound of formula III is mono(C 1-6 alkyl)carbonate, more preferably acetate.
- the present invention also relates to a compound of formula II
- the compound of formula II has an enantiomeric or diastereomeric purity of 96% to 100%; preferably 97%.
- the present invention also relates to a compound of formula V
- R 2 is as defined above; and R 3 is para-nitrobenzyl or allyl; preferably allyl.
- the compound of formula V has an enantiomeric or diastereomeric purity of 96% to 100%; preferably 97%.
- the A 1 moiety of said R 2 is C 6-10 aryl, such as phenyl.
- the A 1 moiety of said R 2 is C 1-10 heteroaryl selected from the group consisting of furyl, thienyl, pyridyl, aminothiazolyl and aminothiadiazolyl, in which the amino moiety of said aminothiazolyl or aminothiadiazolyl is optionally protected.
- the A 1 moiety of said R 2 is C 1-10 heterocyclyl; such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]-heptanyl, azetidinyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dioxanyl, 1,3-dioxolanyl, 1,4-dithianyl, hexahydroazepinyl, hexahydropyrimidine, imidazolidinyl, imidazolinyl, isoxazolidinyl, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, 2H-pyranyl, 4H-pyranyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, quinolizinyl,
- the A 2 moiety of said R 2 is hydrogen or C 1-6 alkyl.
- a preferred embodiment of the invention includes each of the foregoing generic and sub-generic embodiments wherein the A 2 moiety of said R 2 is C 1-6 alkyl, more preferably methyl.
- a compound of the formula III has a formula IIIa
- L is a leaving group, such as halo, methanesulfonyl, dialkylphosphorothioate, such as diethylphosphorothioate or 3-benzthiazolyloxy.
- a compound of the formula III has a formula IIIa, as defined above, wherein L is diethylphosphorothioate or acetate.
- R 2 The optional conversion of R 2 to a different R 2 and the optional formation of a pharmaceutically acceptable salt, can be carried out using methods well known in the art.
- Deprotection can be carried out by any convenient method known in the art such that unwanted side reactions are minimized. Separation of unwanted by-products can be carried out using standard methods known to those skilled in the art (for example, see “Protection of the Amino Group”, in Protective Groups in Organic Synthesis, 2nd Edition, T. W. Greene and P. G. M. Wuts, Ed., Wiley and Sons, Inc. 1991, pp. 309–405).
- the present invention also relates to a method of using a zwitterion intermediate for the preparation of 3-cyclic-ether-substituted cephalosporins.
- Scheme 1 refers to the preparation of compounds of formula I.
- a compound of formula I can be prepared by reacting a compound of formula II with a compound of formula III R 2 -L (III) wherein L is a leaving group, in the presence of a base and a solvent.
- Suitable leaving groups include hydroxy, halo, azido, mono(C 1-6 alkyl)carbonate, (C 1-6 alkyl)carboxylate, (C 6-10 aryl)carboxylate, mono-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di-(C 6-10 aryl)(C 1-6 alkyl)carboxylate, di(C 1-6 alkyl)phosphorothioate, (C 1-6 alkyl)sulfonyl, mono-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, di-(C 1-6 alkyl)(C 6-10 aryl)sulfonyl, (C 1-6 alkyl)-(CO)—S—, cyano- 1-6 alkoxy, C 6-10 aryloxy, 3-benzthiazolyloxy, 8-quinolinyloxy or N-oxy-succinimidyl.
- the leaving group is di(C
- Suitable bases include diisopropylethylamine or sodium hydroxide, preferably sodium hydroxide, most preferably 15% aqueous sodium hydroxide.
- Suitable solvents include water, acetone, tetrahydrofuran, ethyl acetate, dimethylacetamide, dimethylformamide, acetonitrile, methylene chloride, 1,2-dichloroethane, or mixtures thereof; preferably a mixture of water and acetone, most preferably a mixture of 1:1.3 of water and acetone.
- the aforesaid reaction can be conducted at a temperature of about ⁇ 40° C. to about 30° C.; preferably about 20° C. to about 30° C.
- the aforesaid reaction can be conducted for a period from about 1 hour to about 24 hours, preferably for about 3 hours.
- the aforesaid reaction can be effected in the presence of an acid binding agent, for example a tertiary amine (such as triethylamine), pyridine (such as 2,6-lutidine or 4-dimethylaminopyridine), or dimethylaniline.
- an acid binding agent for example a tertiary amine (such as triethylamine), pyridine (such as 2,6-lutidine or 4-dimethylaminopyridine), or dimethylaniline.
- the aforesaid reaction can also be carried out in the presence of molecular sieves, an inorganic base (such as calcium carbonate or sodium bicarbonate) or an oxirane, which binds the hydrogen gas liberated in the aforesaid reaction.
- the oxirane is preferably C 1-6 alkyl-1,2-alkylene oxide, such as ethylene oxide or propylene oxide.
- the aforesaid reaction can be conducted in the presence of a coupling agent.
- Suitable coupling agents include N,N′-diethylcarbodiimide, N,N′-dipropyl carbodiimide, N,N′-diisopropylcarbodiimide, N,N′-dicyclohexylcarbodiimide, N-ethyl-N′-[3-(dimethylamino)propyl]carbodiimide, N,N′-carbonyldiimidazole, and N,N′-carbonyldithiazole.
- the coupling agent is N,N′-diethylcarbodiimide.
- the reaction is conducted in the absence of any couplings agents.
- the aforesaid reaction can be conducted in the presence of a catalyst.
- Suitable catalysts include a Lewis acid, such as boron trihalide or aluminum halide.
- the reaction is conducted in the absence of any catalysts.
- the compound of formula III can be prepared by methods known in the art. Suitable methods include those described, for example, in U.K. Patent No. 2 107 307 B, U.K. Patent Specification No. 1,536,281 and U.K. Patent Specification No. 1,508,064.
- the compound of formula III i.e. R 2 L
- R 2 has a formula:
- A is 2-aminothiazol-4-yl
- a 2 is methyl
- L is (C 1-6 alkyl)sulfonyl, such as methylsulfonyl, or di(C 1-6 alkyl)phosphorothioate, such as diethylphosphorothioate, can be prepared by reacting a compound of formula IIIb
- (C 1-6 alkyl)sulfonylhalide such as methanesulfonylchloride
- di(C 1-6 alkyl)thiophosphonic acid such as diethylthiophoshonic acid.
- the compound of formula III is diethylthiophoshoryl-[Z]-2-aminothiazol-4-yl-methoxylamino (DAMA), which can be prepared according to the methods described in U.S. Pat. No. 5,567,813 and EP 628561.
- DAMA diethylthiophoshoryl-[Z]-2-aminothiazol-4-yl-methoxylamino
- Scheme 2 refers to the preparation of a compound of formula II.
- a compound of formula II can be prepared by reacting a compound of formula IV, wherein R 3 preferably para-nitrobenzyl ester; and X is preferably chloro; with a suitable deprotecting agent in a solvent.
- Suitable deprotecting agents include sodium dithionite or a catalytic hydrogenating agent, such as hydrogen gas over 10% palladium on carbon.
- Suitable solvents include acetone, water, tetrahydrofuran, methylene chloride or mixtures thereof.
- the solvent is a mixture of 3:1 acetone and water.
- the aforesaid reaction can be conducted at a temperature of about 0° C. to about 45° C., preferably about 45° C.
- the aforesaid reaction can be conducted for a period from about 1 hour to about 24 hours, preferably from about 1 hour.
- a compound of formula IV can be prepared by various synthetic methods such as those described in the United States Non-Provisional Patent Application entitled “Process and Ester Derivatives Useful For Preparation of Cephalosporins”, filed Dec. 4, 2001. These methods are described hereinbelow in Schemes 4–6.
- Scheme 3 refers to an alternative process of preparation of a compound of formula I.
- a compound of formula I can be prepared by reacting a compound of formula V, wherein R 3 is preferably allyl; with a suitable deprotecting agent in a solvent.
- Suitable deprotecting agents include sodium dithionite or tetrakistriphenyl phosphine palladium (0).
- Suitable solvents include acetone, water, tetrahydrofuran, methylene chloride or mixtures thereof.
- the solvent is methylene chloride.
- the aforesaid reaction can be conducted at a temperature of about 0° C to about 45° C.
- the aforesaid reaction can be conducted for a period from about 1 hour to about 24 hours.
- a compound of formula V can be prepared by reacting a compound of formula IV, wherein R 3 is preferably allyl; and X is preferably chloro; with a compound of formula III R 2 -L (III) in a solvent.
- Suitable solvents for the aforesaid reaction include methylene chloride, tetrahydrofuran or mixtures thereof.
- the solvent is methylene chloride.
- the aforesaid reaction can be conducted in the presence of a coupling agent.
- Suitable coupling agents include N,N′-diethylcarbodiimide, N,N′-dipropyl carbodiimide, N,N′-diisopropylcarbodiimide, N,N′-dicyclohexylcarbodiimide, N-ethyl-N′-[3-(dimethylamino)propyl]carbodiimide, N,N′-carbonyldiimidazole, or N,N′-carbonyldithiazole.
- the coupling agent is N,N′-diethylcarbodiimide.
- the aforesaid reaction is conducted without any coupling agents.
- the aforesaid reaction can be conducted in the presence of a catalyst.
- Suitable catalysts include a Lewis acid, such as boron trihalide or aluminum halide.
- the aforesaid reaction is conducted without any catalysts.
- the aforesaid reaction can be conducted at a temperature of about ⁇ 40° C. to about +40° C., preferably about +20° C. to about +40° C.
- the aforesaid reaction can be conducted for a period from about 1 hour to about 24 hours; preferably about 24 hours.
- a compound of formula IV can be prepared as described below in the description for Schemes 4–6.
- Scheme 4 refers to the preparation of a compound of formula (IV).
- a compound of formula (IV) wherein R 1 is preferably para-nitrobenzyl can be prepared by reaction of a compound of formula (VI) wherein R 1 is preferably para-nitrobenzyl, and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl, with an acid in a solvent.
- Suitable acids include Lewis Acids, such as phosphorus pentachloride or phosphorus pentabromide, preferably phosphorus pentachloride.
- Suitable solvents include toluene, xylene, tetrahydrofuran, methylene chloride or acetonitrile; preferably methylene chloride.
- the aforesaid process can be conducted at a temperature of about ⁇ 40° C. to about +40° C.
- the aforesaid process is conducted for a period of from about 1 hour to about 24 hours.
- a compound of formula (VI) wherein R 1 is preferably para-nitrobenzyl, and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl can be prepared by cyclizing a compound of formula (VIIa), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; by heating said compound of formula (VIIa) in a solvent.
- the aforesaid process for the conversion of compounds of formula (VIIa) into compounds of formula (VI) is a so called intramolecular Wittig-type reaction and is typically conducted by heating the above compound of formula (VIIa).
- Suitable solvents include toluene, xylene, tetrahydrofuran, methylene chloride and acetonitrile, preferably methylene chloride.
- the aforesaid process is conducted at a temperature of from about 40° C. to about 160° C.
- the aforesaid process is conducted for a period of from about 1 hour to about 24 hours, preferably about 16 hours.
- the aforesaid conversion of the compound of formula (VIIa) to the compound of formula (IV) can be performed as a two step process in which the compound of formula (VI) may be isolated but is preferably carried out as a one step reaction without isolation of the phosphorus ylide.
- Scheme 5 refers to the preparation of compounds of the formula (VIIa), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; by the processes of the present invention.
- Compounds of the formula (VIIa) are intermediates useful in the preparation of compounds of formula (IV) in Scheme 4.
- the aforesaid compound of formula (VIIa) can be prepared by reacting a compound of formula (VIIb), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; and X is preferably chloro, with trimethylphoshine, in a solvent, optionally in the presence of a suitable base.
- Suitable solvents include tetrahydrofuran, acetonitrile and methylene chloride, preferably tetrahydrofuran.
- Suitable bases include imidazole, 2,6-lutidine, pyridine, N-methymorpholine or sodium bicarbonate, preferably sodium bicarbonate.
- the reaction is conducted with the suitable base during work up.
- the aforesaid process is conducted at a temperature of from about ⁇ 40° C. to about ⁇ 20° C.
- the aforesaid process is conducted for a period of from about 30 minutes to about 1 hour.
- a compound of formula (VIIb), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (VIIc), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; with a halogenating agent in the presence of a base in a solvent.
- Suitable halogenating agents include thionyl chloride, thionyl bromide, phosphorus tribromide or phosphorus trichloride, preferably thionyl chloride.
- Suitable bases include pyridine, 2,6-lutidine, N-methylmorpholine or imidazole, preferably 2,6-lutidine.
- Suitable solvents include tetrahydrofuran or methylene chloride, preferably methylene chloride.
- the aforesaid process is conducted at a temperature of from about ⁇ 40° C. to about ⁇ 20° C., preferably about ⁇ 20° C.
- the aforesaid process is conducted for a period of from about 15 minutes to about 1 hour, preferably about 1 hour.
- a compound of formula (VIIc), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (IX), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; with a compound of formula (VIII)
- Y is a leaving group such as bromo, chloro, fluoro, iodo or tosylate, preferably bromo, in a solvent.
- Suitable solvents include alcohol, such as methanol, ethanol and propanol; methylene chloride; acetone; dimethylformamide; or mixtures thereof.
- the aforesaid process is conducted at a temperature of from about 10° C. to about 25° C.
- the aforesaid process is conducted for a period of from about 4 hours to about 24 hours.
- the compound of formula (VIII) can be prepared in situ by reacting the corresponding carboxylic acid of formula (VIIIb)
- halogenating agent in methanol or water solution; and subsequently exposing the solution to an acid, preferably para-toluene sulfonic acid.
- Suitable halogenating agents include bromine, chlorine or iodine, preferably bromine.
- Scheme 6 refers to-the preparation of compounds of the formula (IX), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; by the processes of the present invention.
- Compounds of the formula (IX) are useful intermediates in the preparation of compounds of formula (IV), via compounds of the formula (VIIa).
- the conversion of compounds of formula (IX) into compounds of formula I are described in Schemes 1 and 2.
- a compound of formula (IX) can be prepared by reacting a compound of formula (Xa), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; with an acid in a solvent.
- Suitable acids include para-toluene sulfonic acid and methane sulfonic acid, preferably para-toluene sulfonic acid.
- Suitable solvents include methylene chloride, tetrahydrofuran, acetone or mixtures thereof, preferably methylene chloride.
- the aforesaid process is conducted at a temperature of from about 20° C. to about 25° C.
- the aforesaid process is conducted for a period of from about 2 hours to about 24 hours.
- a compound of formula (Xa), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (Xb), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably.
- Suitable reducing agents include sodium borohydride, sodium cyanoborohydride, borane and sodium triacetoxy borohydride, preferably sodium triacetoxyborohydride or sodium borohydride.
- Suitable solvents include acetic acid, methylene chloride, tetrahydrofuran, alcohol (such as isopropanol) or mixtures thereof.
- the reducing agent is sodium triacetoxy borohydride, preferably the solvent is methylene chloride.
- the solvent is acetic acid.
- the aforesaid process is conducted at a temperature of from about 20° C. to about 66° C.
- the aforesaid process is conducted for a period of from about 4 hours to about 24 hours.
- the compound of formula (Xa), wherein R 1 is preferably para-nitrobenzyl; and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (XV), wherein R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl, with a compound of formula (XIV),
- R 1 is preferably para-nitrobenzyl, in the presence of a base in a solvent.
- Suitable bases include diisopropylamine, triethylamine, pyridine and 2,6-lutidine; preferably triethylamine; more preferably the triethylamine is catalytic.
- Suitable solvents include methylene chloride, tetrahydrofuran or mixtures thereof. The aforesaid process is conducted at a temperature of from about 20° C. to about 25° C. The aforesaid process is conducted for a period of from about 30 minutes to about 2 hours, preferably about 1 hour.
- Said compound of formula (XII) is prepared by reacting said compound of formula (XV) with a compound of formula (XIII)
- each of L 1 and L 2 is a leaving group, such as halo, preferably chloro, in a solvent, optionally in the presence of a base.
- Suitable solvents include methylene chloride, tetrahydrofuran, or mixtures thereof, preferably methylene chloride.
- Suitable bases include diisopropylamine, triethylamine, pyridine and 2,6-lutidine, preferably triethylamine.
- the aforesaid process is conducted at a temperature of about ⁇ 78° C. to about 25° C., preferably about ⁇ 78° C.
- the aforesaid process is conducted for a period of from about 5 minutes to about 10 minutes, preferably about 5 minutes.
- the compound of formula (XII) may be isolated, or may be carried on to the next step without isolation. Preferably the compound of formula (XII) is isolated.
- R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (Xc), wherein R 1 is preferably para-nitrobenzyl; R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; R 3 is preferably C 1-6 alkyl, such as methyl; and R 4 is preferably C 1-6 alkyl, such as methyl; with an oxidizing agent, in a solvent. Suitable oxidizing agents include ozone. Suitable solvents include methylene chloride, tetrahydrofuran or mixtures thereof, preferably methylene chloride. The aforesaid process is conducted at a temperature of about ⁇ 70° C. The aforesaid process is conducted for a period of from about 1 hour to about 24 hours.
- a compound of formula (Xc) is commercially available.
- a compound of formula (Xb), wherein R 1 is preferably para-nitrobenzyl, and R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; can be prepared by reacting a compound of formula (XV), wherein R 2 is preferably C 6-10 arylC 1-6 alkyl, such as benzyl; with a compound of formula (XVI)
- R 1 is preferably para-nitrobenzyl
- L 3 is a leaving group, such as halo, preferably chloro, in a solvent in the presence of a base.
- Suitable solvents include methylene chloride, tetrahydrofuran or mixtures thereof.
- Suitable bases include diisopropylamine, triethylamine, pyridine or 2,6-lutidine.
- the aforesaid process is conducted at a temperature of from about ⁇ 40° C. to about 25° C.
- the aforesaid process is conducted for a period of about 5 minutes to 15 minutes.
- solvates can be formed.
- This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that can be produced by processes such as lyophilization.
- the compounds of formula (I) are useful for the preparation of a 3-cyclic-ether-substituted cephalosporin, i.e., the active compound.
- the active compound possesses activities against gram positive and gram negative bacteria.
- Methods for assaying the activity and methods for formulating and administering the active compounds are disclosed in U.S. Pat. No. 6,020,329, issued Feb. 1, 2000. Methods of treatments are also described in the aforesaid patent.
- Method B from ALLYL-7-(2-(2-AMINOTHIAZOL4-YL)-2-METHOXYIMINO)-3-TETRAHYDROFURAN-2-YL)-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLATE, BENZENE SULPHINIC ACID SALT
- the toluene was then stripped under vacuo at a maximum temperature of 60° C.
- Ethyl acetate was then added and was then stripped under vacuo at a maximum temperature of 60° C.
- To the semi solid oil was added tert-butyl methyl ether (2.5 liters) and the solution stirred overnight.
- the crystalline product was filtered off and washed with further tert-butyl methyl ether (0.3 liters).
- the mother liquors were concentrated and resubjected to silica chromatography (dissolved in 5 liters of toluene, added onto silica, eluted with 15 liters of toluene) and crystallized in the same fashion to afford a second crop.
- the product was isolated as a white crystalline solid. Yields range from 70% to 80%.
- the solution was stirred overnight, diluted with methylene chloride (10 liters) and washed twice with water (10 liters total) then once with saturated sodium chloride (10%, 10 liter). After drying over sodium sulphate, the solution was concentrated under vacuo at a maximum temperature of 40° C. to ensure dryness. The solution was redissolved in tetrahydrofuran (5 liter) for use in the next step. If storage was required, the tetrahydrofuran solution was stored and dried before use.
Abstract
-
- A1 and A2 have the meanings given in the specification by reacting compound of formula II:
Description
with a compound of the formula III
R2L (III)
wherein R2 is as defined above, and L is a leaving group, in the presence of a solvent and a base. Optionally, the aforesaid process may be performed in the presence of a coupling agent and a catalyst.
wherein R3 is para-nitrobenzyl or allyl, preferably para-nitrobenzyl; and X is halo, preferably chloro; with a suitable deprotecting agent; in the presence of a solvent.
In one embodiment of the invention, the compound of formula II has an enantiomeric or diastereomeric purity of 96% to 100%; preferably 97%.
wherein L is a leaving group, such as halo, methanesulfonyl, dialkylphosphorothioate, such as diethylphosphorothioate or 3-benzthiazolyloxy.
R2-L (III)
wherein L is a leaving group, in the presence of a base and a solvent.
wherein A is 2-aminothiazol-4-yl, A2 is methyl, and L is (C1-6alkyl)sulfonyl, such as methylsulfonyl, or di(C1-6alkyl)phosphorothioate, such as diethylphosphorothioate, can be prepared by reacting a compound of formula IIIb
with (C1-6alkyl)sulfonylhalide, such as methanesulfonylchloride, or di(C1-6alkyl)thiophosphonic acid, such as diethylthiophoshonic acid.
R2-L (III)
in a solvent.
wherein Y is a leaving group such as bromo, chloro, fluoro, iodo or tosylate, preferably bromo, in a solvent. Suitable solvents include alcohol, such as methanol, ethanol and propanol; methylene chloride; acetone; dimethylformamide; or mixtures thereof. The aforesaid process is conducted at a temperature of from about 10° C. to about 25° C. The aforesaid process is conducted for a period of from about 4 hours to about 24 hours.
by reacting said compound of formula (VIIIa) with a halogenating agent, such as thionyl chloride or phophorus tribromide, to form the corresponding acid halide (such as chloroformyltetrahydrofuran or bromoformyltetrahydrofuran). Said acid halide is reacted with diazomethane to form a diazo compound. The resulting diazo compound is then treated with hydrogen chloride or hydrogen bromide to form the corresponding compound of formula (VIII).
with a halogenating agent in methanol or water solution; and subsequently exposing the solution to an acid, preferably para-toluene sulfonic acid. Suitable halogenating agents include bromine, chlorine or iodine, preferably bromine.
wherein R1 is preferably para-nitrobenzyl, in the presence of a base in a solvent. Suitable bases include diisopropylamine, triethylamine, pyridine and 2,6-lutidine; preferably triethylamine; more preferably the triethylamine is catalytic. Suitable solvents include methylene chloride, tetrahydrofuran or mixtures thereof. The aforesaid process is conducted at a temperature of from about 20° C. to about 25° C. The aforesaid process is conducted for a period of from about 30 minutes to about 2 hours, preferably about 1 hour.
R1—OH (XI)
wherein R1 is preferably para-nitrobenzyl; in a solvent, in the presence of a base.
wherein each of L1 and L2 is a leaving group, such as halo, preferably chloro, in a solvent, optionally in the presence of a base. Suitable solvents include methylene chloride, tetrahydrofuran, or mixtures thereof, preferably methylene chloride. Suitable bases include diisopropylamine, triethylamine, pyridine and 2,6-lutidine, preferably triethylamine. The aforesaid process is conducted at a temperature of about −78° C. to about 25° C., preferably about −78° C. The aforesaid process is conducted for a period of from about 5 minutes to about 10 minutes, preferably about 5 minutes.
wherein R1 is preferably para-nitrobenzyl, and L3 is a leaving group, such as halo, preferably chloro, in a solvent in the presence of a base. Suitable solvents include methylene chloride, tetrahydrofuran or mixtures thereof. Suitable bases include diisopropylamine, triethylamine, pyridine or 2,6-lutidine. The aforesaid process is conducted at a temperature of from about −40° C. to about 25° C. The aforesaid process is conducted for a period of about 5 minutes to 15 minutes.
Sodium 7-(2-(2-aminothiazol-4-yl)-2-methoxyimino)-3-(tetrahydrofuran-2-yl)-8-oxo-5- |
thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate |
No. | Structure | Molecular Weight |
1 | | 453.48 |
Method A: from 7-AMINO-8-OXO-3-(TETRAHYDROFURAN-2-YL)-5-THIA-1-AZA-BICYCLO[4.2.0]OCTA-1(6),2,4-TRIENE-2-CARBOXYLIC ACID
7-Amino-8-oxo-3-(tetrahydrofuran-2-yl)-5-thia-1-aza-bicyclo[4.2.0]octa- |
1(6),2,4-triene-2-carboxylic acid |
No. | Structure | Molecular Weight |
2 |
|
270.29 |
Allyl-7-(2-(2-Aminothiazol-4-yl)-2-methoxyimino)-3-tetrahydrofuran-2-yl)-8-oxo- |
5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate, benzene sulphinic acid salt |
No. | Structure | Molecular Weight |
3 | | 493.56(634.62 as benzenesulphinic acid salt) |
Preparation 1: Allyl-7-phenylacetamido-3-(tetrahydrofuran-2-yl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]-oct-2-ene-2-carboxylate
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/776,795 US7129350B2 (en) | 2000-12-04 | 2004-02-11 | Coupling process and intermediates useful for preparing cephalosporins |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25101400P | 2000-12-04 | 2000-12-04 | |
US10/006,279 US20020198375A1 (en) | 2000-12-04 | 2001-12-04 | Coupling process and intermediates useful for preparing cephalosporins |
US10/776,795 US7129350B2 (en) | 2000-12-04 | 2004-02-11 | Coupling process and intermediates useful for preparing cephalosporins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/006,279 Continuation US20020198375A1 (en) | 2000-12-04 | 2001-12-04 | Coupling process and intermediates useful for preparing cephalosporins |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040167327A1 US20040167327A1 (en) | 2004-08-26 |
US7129350B2 true US7129350B2 (en) | 2006-10-31 |
Family
ID=22950114
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/006,279 Abandoned US20020198375A1 (en) | 2000-12-04 | 2001-12-04 | Coupling process and intermediates useful for preparing cephalosporins |
US10/776,795 Expired - Lifetime US7129350B2 (en) | 2000-12-04 | 2004-02-11 | Coupling process and intermediates useful for preparing cephalosporins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/006,279 Abandoned US20020198375A1 (en) | 2000-12-04 | 2001-12-04 | Coupling process and intermediates useful for preparing cephalosporins |
Country Status (18)
Country | Link |
---|---|
US (2) | US20020198375A1 (en) |
EP (1) | EP1339722A1 (en) |
JP (1) | JP2004520293A (en) |
KR (1) | KR100526379B1 (en) |
CN (1) | CN1243755C (en) |
AR (1) | AR035511A1 (en) |
AU (2) | AU2394302A (en) |
BR (1) | BR0115870A (en) |
CA (1) | CA2436848C (en) |
CZ (1) | CZ20031525A3 (en) |
HK (1) | HK1059435A1 (en) |
HU (1) | HUP0400642A3 (en) |
IL (1) | IL155714A0 (en) |
MX (1) | MXPA03004937A (en) |
PL (1) | PL362144A1 (en) |
RU (1) | RU2237670C1 (en) |
WO (1) | WO2002046198A1 (en) |
ZA (1) | ZA200303670B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070208172A1 (en) * | 2004-03-09 | 2007-09-06 | Pfizer Inc. | Process for Preparing Cephalosporin Intermediates Using Alpha-Iodo-1-Azetidineacetic Acid Esters and Trialkylphosphites |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1340751A4 (en) * | 2000-12-04 | 2005-07-27 | Fujisawa Pharmaceutical Co | Process for producing anhydride of aminothiazole derivative |
US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
CN103874697A (en) | 2011-08-03 | 2014-06-18 | 协和发酵麒麟株式会社 | Dibenzooxepin derivative |
CN102718779B (en) * | 2012-05-25 | 2015-07-29 | 深圳致君制药有限公司 | The synthetic method of ceftiaoxline sodium for injection and preparation method thereof, bulk drug ceftizoxime sodium |
CN105254648B (en) * | 2015-11-13 | 2018-04-03 | 广东温氏大华农生物科技有限公司 | A kind of synthetic method of cephalo dimension star and its sodium salt |
WO2018229580A1 (en) * | 2017-06-14 | 2018-12-20 | Aurobindo Pharma Ltd | An improved process for the preparation of cefovecin sodium |
EP3774003A4 (en) * | 2018-04-04 | 2022-01-05 | Terapore Technologies, Inc. | Encapsulating particle fractionation devices and systems and methods of their use |
US11051804B2 (en) * | 2018-07-02 | 2021-07-06 | DePuy Synthes Products, Inc. | Orthopedic fixation system and method of use thereof |
GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
CN110396034A (en) * | 2019-07-31 | 2019-11-01 | 上海应用技术大学 | A kind of preparation method of allyl compound |
CN111187284A (en) * | 2020-03-10 | 2020-05-22 | 赵俊瑶 | Preparation method of cefaclor |
CN111892612A (en) * | 2020-07-31 | 2020-11-06 | 重庆医药高等专科学校 | Intermediate isomeride for preparing cefuroxime from penicillin sylvite and preparation method thereof |
CN112321611B (en) * | 2020-10-29 | 2022-05-06 | 湖北凌晟药业有限公司 | Preparation method of cefixadine mother nucleus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001696A1 (en) * | 1990-07-24 | 1992-02-06 | Beecham Group Plc | Cephalosporins and homologues, preparations and pharmaceutical compositions |
US6825344B2 (en) * | 2000-08-03 | 2004-11-30 | Pfizer Inc. | Process for the preparation of cephalosporin compounds and synthetic intermediates |
US20040267008A1 (en) * | 2000-12-04 | 2004-12-30 | Pfizer Inc | Process and ester derivatives useful for preparation of cephalosporins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001997A (en) * | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
GB9212609D0 (en) * | 1992-06-13 | 1992-07-29 | Smithkline Beecham Plc | Novel compounds |
GB9424847D0 (en) * | 1994-12-09 | 1995-02-08 | Smithkline Beecham Plc | Novel process |
GB2300856A (en) * | 1995-05-16 | 1996-11-20 | Pfizer Ltd | Beta-lactam preparation |
-
2001
- 2001-11-22 PL PL01362144A patent/PL362144A1/en not_active Application Discontinuation
- 2001-11-22 BR BR0115870-8A patent/BR0115870A/en not_active IP Right Cessation
- 2001-11-22 HU HU0400642A patent/HUP0400642A3/en unknown
- 2001-11-22 IL IL15571401A patent/IL155714A0/en unknown
- 2001-11-22 WO PCT/IB2001/002225 patent/WO2002046198A1/en active IP Right Grant
- 2001-11-22 AU AU2394302A patent/AU2394302A/en active Pending
- 2001-11-22 CA CA002436848A patent/CA2436848C/en not_active Expired - Fee Related
- 2001-11-22 RU RU2003116519/04A patent/RU2237670C1/en active
- 2001-11-22 CN CNB018199623A patent/CN1243755C/en not_active Expired - Fee Related
- 2001-11-22 JP JP2002547935A patent/JP2004520293A/en active Pending
- 2001-11-22 MX MXPA03004937A patent/MXPA03004937A/en active IP Right Grant
- 2001-11-22 EP EP01999227A patent/EP1339722A1/en not_active Withdrawn
- 2001-11-22 AU AU2002223943A patent/AU2002223943B2/en not_active Ceased
- 2001-11-22 CZ CZ20031525A patent/CZ20031525A3/en unknown
- 2001-11-22 KR KR10-2003-7007396A patent/KR100526379B1/en not_active IP Right Cessation
- 2001-12-03 AR ARP010105609A patent/AR035511A1/en not_active Application Discontinuation
- 2001-12-04 US US10/006,279 patent/US20020198375A1/en not_active Abandoned
-
2003
- 2003-05-13 ZA ZA200303670A patent/ZA200303670B/en unknown
-
2004
- 2004-02-11 US US10/776,795 patent/US7129350B2/en not_active Expired - Lifetime
- 2004-03-25 HK HK04102215A patent/HK1059435A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001696A1 (en) * | 1990-07-24 | 1992-02-06 | Beecham Group Plc | Cephalosporins and homologues, preparations and pharmaceutical compositions |
US6825344B2 (en) * | 2000-08-03 | 2004-11-30 | Pfizer Inc. | Process for the preparation of cephalosporin compounds and synthetic intermediates |
US20040267008A1 (en) * | 2000-12-04 | 2004-12-30 | Pfizer Inc | Process and ester derivatives useful for preparation of cephalosporins |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070208172A1 (en) * | 2004-03-09 | 2007-09-06 | Pfizer Inc. | Process for Preparing Cephalosporin Intermediates Using Alpha-Iodo-1-Azetidineacetic Acid Esters and Trialkylphosphites |
Also Published As
Publication number | Publication date |
---|---|
RU2237670C1 (en) | 2004-10-10 |
AU2002223943B2 (en) | 2006-10-05 |
JP2004520293A (en) | 2004-07-08 |
US20020198375A1 (en) | 2002-12-26 |
CN1478093A (en) | 2004-02-25 |
KR100526379B1 (en) | 2005-11-08 |
CN1243755C (en) | 2006-03-01 |
KR20030070043A (en) | 2003-08-27 |
MXPA03004937A (en) | 2003-09-10 |
CA2436848C (en) | 2008-12-02 |
US20040167327A1 (en) | 2004-08-26 |
PL362144A1 (en) | 2004-10-18 |
CZ20031525A3 (en) | 2004-04-14 |
ZA200303670B (en) | 2004-05-13 |
HUP0400642A3 (en) | 2010-03-29 |
EP1339722A1 (en) | 2003-09-03 |
HK1059435A1 (en) | 2004-07-02 |
CA2436848A1 (en) | 2002-06-13 |
WO2002046198A1 (en) | 2002-06-13 |
BR0115870A (en) | 2004-02-03 |
AU2394302A (en) | 2002-06-18 |
HUP0400642A2 (en) | 2004-06-28 |
AR035511A1 (en) | 2004-06-02 |
IL155714A0 (en) | 2003-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7129350B2 (en) | Coupling process and intermediates useful for preparing cephalosporins | |
KR940000112B1 (en) | 3-substituted cephem compounds | |
AU2002223943A1 (en) | Coupling process and intermediates useful for preparing cephalosphorins | |
NO881531L (en) | Acyl. | |
US5804577A (en) | Cephalosporin derivatives | |
US5412094A (en) | Bicyclic beta-lactam/paraben complexes | |
US4377590A (en) | Derivatives of ampicillin and amoxicillin with beta-lactamase inhibitors | |
CA1109859A (en) | Thiooxime cephalosporin and penicillin derivatives | |
EP1339723B1 (en) | Process and ester derivatives useful for preparation of cephalosporins | |
US6001996A (en) | Complexes of cephalosporins and carbacephalosporins with parabens | |
AU2002223929A1 (en) | Process and ester derivatives useful for preparation of cephalosporins | |
EP0355821A2 (en) | A process for preparing cephem prodrug esters | |
JPS63152383A (en) | 2-oxa-isocephem derivative | |
KR960002856B1 (en) | 2-oxa-isocephem compounds, the compositions containing the same and the process for preparing the same | |
US4521598A (en) | 3-Azidocephalosporins | |
JPS62270589A (en) | Novel cephalosporin derivative | |
EP0761673A1 (en) | Cephalosporin derivatives | |
US4560749A (en) | Cephem-3-imidates and 3-amidines | |
KR960011777B1 (en) | Novel crystalline cephalosporine derivatives and the process for preparing them | |
NZ299327A (en) | 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetylamino]-3-[1-(substitut ed)-2-oxopyrrolidin-3-ylidenemethyl]-8-oxo-5-thia-1-azabicyclo[4. 2.0]oct-2-ene-2-carboxylic acid (cephalosporin) derivatives | |
EP0162396A2 (en) | Process for the preparation of 7-amino-3-(3-formamidopyridinium)methyl-3-cephem-4-carboxylate, and its use in the synthesis of beta-lactam antibiotics | |
MXPA96004017A (en) | Derivatives of cephalosporine and procedure for its preparation | |
JPH0676415B2 (en) | Novel cephalosporins and their salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PFIZER, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLBERG, JUAN C.;ZENONI, MAURIZIO;FOGLIATO, GIOVANNI;AND OTHERS;REEL/FRAME:018232/0403;SIGNING DATES FROM 20060823 TO 20060829 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
REIN | Reinstatement after maintenance fee payment confirmed | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20101031 |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20120501 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: AH USA 42 LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PFIZER INC.;REEL/FRAME:029609/0336 Effective date: 20121001 |
|
AS | Assignment |
Owner name: ZOETIS LLC, NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:AH USA 42 LLC;REEL/FRAME:030119/0866 Effective date: 20130201 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: ZOETIS SERVICES LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZOETIS LLC;REEL/FRAME:035651/0817 Effective date: 20150426 |
|
AS | Assignment |
Owner name: ZOETIS SERVICES LLC, NEW YORK Free format text: ASIGNEE ADDRESS CHANGE;ASSIGNOR:ZOETIS SERVICES LLC;REEL/FRAME:042190/0061 Effective date: 20161027 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553) Year of fee payment: 12 |